Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,
about
Glucagon-like peptide analogues for type 2 diabetes mellitusIncretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesThe Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in KoreaEfficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitusExenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33)Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Incretin response in Asian type 2 diabetes: Are Indians different?Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with/without metformin.Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients.Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-AnalysisLong-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model StudyThe efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trialsLiraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference.Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulationsCardiovascular biology of the incretin system.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysisEffects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and PharmacodynamicsEfficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.Standards of care for type 2 diabetes in China.Liraglutide: a review of its use in the management of type 2 diabetes mellitus.Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.Red carpeting the newer antidiabetics.Drug-induced hypoglycaemia in type 2 diabetes.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Direct cardiovascular effects of glucagon like peptide-1.The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis.Cost effectiveness of liraglutide in type II diabetes: a systematic review.Implications of incretin-based therapies on cardiovascular disease.Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science.Clinical experience with Liraglutide in 196 patients with type 2 diabetes from a tertiary care center in India.Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
P2860
Q24235918-982211BF-5014-4F68-BCB3-42FF4BABC305Q24568148-F94692F4-A3B4-4035-A892-8DC0668FE506Q26852590-E7F6C78C-93C5-4723-B824-0F2EA0D6C440Q28088578-880AA18D-B51D-482D-9B1E-4D80AEBC9F65Q30558739-2ACD04AA-F524-463C-8BDE-9B5B440DBB08Q34264359-F87E3F84-F7D7-44DF-8928-FC44D891E682Q34265490-CFB5FEB0-8EF4-4628-92FC-02707DA7F4CAQ34878323-DF50D4D6-7426-4B91-9D10-EFB539FA010BQ35035176-3E3B3A32-3F12-45F8-ADEF-9CA00B8E8009Q35080171-9EDD2248-9CFB-4007-9535-229170BA30AFQ35146648-F96E2816-555C-48EF-83E3-CA55DBF278B9Q35192188-5D840096-D6D1-4EF8-8EEB-71DFA6A23D12Q36011993-EB7BB48E-CB01-41DC-8B55-C39936EEE8D1Q36053080-AE4768AF-8CF6-49ED-A004-D7A2BCBAEAE5Q36124485-F9BF8F37-A0F1-401C-BC3F-C3D3290A76DAQ36139090-03EA61E4-628D-4573-A1D5-3595F38AD9A6Q36303786-63E5007C-D069-4F36-A623-19B068072B58Q36424233-890DEC2F-6CAC-4FC2-9766-21884318AEDCQ36484283-E74D5456-068C-445D-8FC2-A402BF755023Q36498624-9495CC3E-7E48-414D-8BF6-4955EB820945Q36520655-65BFC06B-DFCF-41A4-BE06-77E5BD2DD321Q36584204-60CB28C5-8F89-4341-B621-46CC314BB8F3Q36924102-02BA6990-6844-4CEE-BDC2-FBDB137B9E31Q37375690-8A0A5B78-76AC-4DFF-A4B5-CBA3DD0C6745Q37412792-16EBAF7F-C4C0-452B-A1AB-A8648118F496Q37956408-A83B102F-414A-4924-A4EC-9834C44F14E8Q38001085-5AF104DF-917D-432B-A236-42AADDE58E5BQ38013105-DF9BEA99-C92C-4439-83DB-E164282EED35Q38018110-E8B7F94D-792D-499D-BD90-B1793D0BCC92Q38036773-046F747E-63A1-4EC0-A44E-8455989863BCQ38132470-BDE274CA-783A-4A48-9ED3-EE2C89FD253DQ38137027-77ED5FDC-4146-4F6D-96F1-1D3704324B0FQ38232870-17E35FF0-D8EE-4922-BF91-EDA327CF033AQ38264374-02E5F5DA-C398-401D-9CAF-6EA4D99D133FQ38264842-18EDD790-C8D3-40CE-92A2-6B2E5549293FQ38320418-1CB2C9AB-2937-4F22-A0C3-03C0FBCE2866Q38546893-D74ED4A5-2EB6-4FD3-A41F-C009971B218EQ38634679-7901957B-C479-480F-9606-D48C240D85F0Q39038925-74C04EE2-5256-4522-ABDC-A23C73A02DD5Q39301000-2630E8E0-DDB6-40E4-A501-462635E73D66
P2860
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Liraglutide provides similar g ...... India: a 16-week, randomized,
@en
Liraglutide provides similar g ...... India: a 16-week, randomized,
@nl
type
label
Liraglutide provides similar g ...... India: a 16-week, randomized,
@en
Liraglutide provides similar g ...... India: a 16-week, randomized,
@nl
prefLabel
Liraglutide provides similar g ...... India: a 16-week, randomized,
@en
Liraglutide provides similar g ...... India: a 16-week, randomized,
@nl
P2093
P921
P1476
Liraglutide provides similar g ...... India: a 16-week, randomized,
@en
P2093
A Bhattacharyya
P356
10.1111/J.1463-1326.2010.01323.X
P577
2011-01-01T00:00:00Z